Nivalis Therapeutics Company Profile (NASDAQ:NVLS)

About Nivalis Therapeutics (NASDAQ:NVLS)

Nivalis Therapeutics logoNivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company's S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company's lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NVLS
  • CUSIP: N/A
  • Web: www.nivalis.com
Capitalization:
  • Market Cap: $36.89 million
  • Outstanding Shares: 15,699,000
Average Prices:
  • 50 Day Moving Avg: $2.45
  • 200 Day Moving Avg: $2.84
  • 52 Week Range: $2.00 - $9.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.64
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.56 per share
  • Price / Book: 0.66
Profitability:
  • EBIDTA: ($29,360,000.00)
  • Return on Equity: -41.72%
  • Return on Assets: -39.02%
Debt:
  • Current Ratio: 12.82%
  • Quick Ratio: 12.82%
Misc:
  • Average Volume: 298,000 shs.
  • Beta: -0.36
  • Short Ratio: 0.44
 

Frequently Asked Questions for Nivalis Therapeutics (NASDAQ:NVLS)

What is Nivalis Therapeutics' stock symbol?

Nivalis Therapeutics trades on the NASDAQ under the ticker symbol "NVLS."

How were Nivalis Therapeutics' earnings last quarter?

Nivalis Therapeutics Inc (NASDAQ:NVLS) announced its quarterly earnings data on Monday, February, 13th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.05. During the same quarter in the previous year, the business earned ($0.42) EPS. View Nivalis Therapeutics' Earnings History.

When will Nivalis Therapeutics make its next earnings announcement?

Nivalis Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Nivalis Therapeutics.

Where is Nivalis Therapeutics' stock going? Where will Nivalis Therapeutics' stock price be in 2017?

6 equities research analysts have issued 1-year price targets for Nivalis Therapeutics' stock. Their predictions range from $3.00 to $20.00. On average, they anticipate Nivalis Therapeutics' share price to reach $9.65 in the next year. View Analyst Ratings for Nivalis Therapeutics.

What are analysts saying about Nivalis Therapeutics stock?

Here are some recent quotes from research analysts about Nivalis Therapeutics stock:

  • 1. According to Zacks Investment Research, "Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado. " (5/5/2017)
  • 2. Cowen and Company analysts commented, "This evening Nivalis and Alpine Immune Sciences announced an agreement to merge." (4/19/2017)

Who are some of Nivalis Therapeutics' key competitors?

When did Nivalis Therapeutics IPO?

(NVLS) raised $60 million in an initial public offering (IPO) on Wednesday, June 17th 2015. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Baird and H.C. Wainwright were co-managers.

Who owns Nivalis Therapeutics stock?

Nivalis Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.63%), Spark Investment Management LLC (1.08%) and Geode Capital Management LLC (0.82%). Company insiders that own Nivalis Therapeutics stock include Bay Master Investors (C Hawkes, David Malcom Rodman, Global Healthcare Mas Jennison, James E Flynn, Janice Troha, Jon Congleton, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Institutional Ownership Trends for Nivalis Therapeutics.

Who bought Nivalis Therapeutics stock? Who is buying Nivalis Therapeutics stock?

Nivalis Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Spark Investment Management LLC and Geode Capital Management LLC. Company insiders that have bought Nivalis Therapeutics stock in the last two years include Bay Master Investors (C Hawkes, Global Healthcare Mas Jennison, James E Flynn, Janice Troha, Jon Congleton, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Insider Buying and Selling for Nivalis Therapeutics.

How do I buy Nivalis Therapeutics stock?

Shares of Nivalis Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nivalis Therapeutics stock cost?

One share of Nivalis Therapeutics stock can currently be purchased for approximately $2.35.

Analyst Ratings

Consensus Ratings for Nivalis Therapeutics (NASDAQ:NVLS) (?)
Ratings Breakdown: 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $9.65 (310.64% upside)

Analysts' Ratings History for Nivalis Therapeutics (NASDAQ:NVLS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/19/2017Cowen and CompanyReiterated RatingHoldMediumView Rating Details
11/29/2016HC WainwrightReiterated RatingBuy$30.00 -> $6.00N/AView Rating Details
11/29/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
11/29/2016Robert W. BairdDowngradeOutperform -> Neutral$29.00 -> $3.00N/AView Rating Details
11/29/2016Stifel NicolausDowngradeBuy -> Hold$16.00 -> $3.25N/AView Rating Details
8/30/2016Piper Jaffray CompaniesReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Nivalis Therapeutics (NASDAQ:NVLS)
Earnings by Quarter for Nivalis Therapeutics (NASDAQ:NVLS)
Earnings History by Quarter for Nivalis Therapeutics (NASDAQ:NVLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017        
2/13/2017Q4 16($0.55)($0.50)ViewN/AView Earnings Details
11/7/2016Q3($0.59)($0.48)ViewN/AView Earnings Details
8/1/2016Q2($0.52)($0.55)ViewN/AView Earnings Details
5/2/2016Q1 16($0.44)($0.51)ViewN/AView Earnings Details
2/29/2016Q4 15($0.36)($0.42)ViewN/AView Earnings Details
11/2/2015Q3 15($0.39)($0.39)ViewN/AView Earnings Details
8/3/2015Q2 2015($0.40)($1.41)ViewN/AView Earnings Details
4/18/2012$0.61$0.61ViewN/AView Earnings Details
2/2/2012$0.47$0.73ViewN/AView Earnings Details
10/26/2011$0.68$0.73ViewN/AView Earnings Details
7/11/2011$0.77$0.79ViewN/AView Earnings Details
4/27/2011$1.03$1.04ViewN/AView Earnings Details
1/31/2011$0.94$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nivalis Therapeutics (NASDAQ:NVLS)
Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-0.89 EPS

Dividends

Dividend History for Nivalis Therapeutics (NASDAQ:NVLS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nivalis Therapeutics (NASDAQ:NVLS)
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 75.85%
Insider Trades by Quarter for Nivalis Therapeutics (NASDAQ:NVLS)
Institutional Ownership by Quarter for Nivalis Therapeutics (NASDAQ:NVLS)
Insider Trades by Quarter for Nivalis Therapeutics (NASDAQ:NVLS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/19/2017Value Fund L P BiotechnologyInsiderBuy78,858$2.30$181,373.40View SEC Filing  
5/11/2017Value Fund L P BiotechnologyInsiderBuy109,034$2.32$252,958.88View SEC Filing  
5/9/2017Robert E ConwayDirectorBuy5,000$2.34$11,700.00View SEC Filing  
5/8/2017Robert E ConwayDirectorBuy15,000$2.28$34,200.00View SEC Filing  
5/5/2017Janice TrohaEVPBuy10,000$2.34$23,400.00View SEC Filing  
5/5/2017Robert E ConwayDirectorBuy20,000$2.30$46,000.00View SEC Filing  
5/4/2017Robert E ConwayDirectorBuy10,000$2.26$22,600.00View SEC Filing  
1/4/2017David Malcom RodmanEVPSell6,687$2.27$15,179.49View SEC Filing  
12/2/2016R Michael CarruthersEVPBuy24,000$2.09$50,160.00View SEC Filing  
10/4/2016David Malcom RodmanEVPSell5,820$7.96$46,327.20View SEC Filing  
7/5/2016David Malcom RodmanCMOSell5,950$4.66$27,727.00View SEC Filing  
6/16/2016Jon CongletonCEOBuy5,000$3.87$19,350.00View SEC Filing  
3/24/2016Jon CongletonCEOBuy5,000$4.22$21,100.00View SEC Filing  
3/22/2016Jon CongletonCEOBuy5,000$4.38$21,900.00View SEC Filing  
12/11/2015Jon CongletonCEOBuy5,000$8.10$40,500.00View SEC Filing  
12/9/2015Robert E ConwayDirectorBuy10,000$8.10$81,000.00View SEC Filing  
6/23/2015James E FlynnInsiderBuy250,000$14.00$3,500,000.00View SEC Filing  
6/22/2015Bay Master Investors (C HawkesMajor ShareholderBuy17,200$14.69$252,668.00View SEC Filing  
6/18/2015Bay Master Investors (C HawkesMajor ShareholderBuy20,400$14.47$295,188.00View SEC Filing  
6/17/2015Global Healthcare Mas JennisonMajor ShareholderBuy26,149$14.00$366,086.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nivalis Therapeutics (NASDAQ:NVLS)
Latest Headlines for Nivalis Therapeutics (NASDAQ:NVLS)
Source:
DateHeadline
americanbankingnews.com logoNivalis Therapeutics Inc (NVLS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 23 at 4:16 PM
americanbankingnews.com logoValue Fund L. P. Biotechnology Buys 78,858 Shares of Nivalis Therapeutics Inc (NVLS) Stock
www.americanbankingnews.com - May 19 at 10:30 PM
americanbankingnews.com logo Brokerages Expect Nivalis Therapeutics Inc (NVLS) Will Announce Earnings of -$0.30 Per Share
www.americanbankingnews.com - May 12 at 8:26 AM
americanbankingnews.com logoInsider Buying: Nivalis Therapeutics Inc (NVLS) Insider Buys 109,034 Shares of Stock
www.americanbankingnews.com - May 11 at 8:04 PM
americanbankingnews.com logoNivalis Therapeutics Inc (NVLS) Director Purchases $34,200.00 in Stock
www.americanbankingnews.com - May 11 at 1:16 PM
americanbankingnews.com logoInsider Buying: Nivalis Therapeutics Inc (NVLS) Director Acquires 5,000 Shares of Stock
www.americanbankingnews.com - May 10 at 4:44 PM
americanbankingnews.com logoJanice Troha Purchases 10,000 Shares of Nivalis Therapeutics Inc (NVLS) Stock
www.americanbankingnews.com - May 9 at 8:26 PM
americanbankingnews.com logoNivalis Therapeutics Inc (NVLS) Director Robert E. Conway Purchases 20,000 Shares
www.americanbankingnews.com - May 9 at 4:50 PM
americanbankingnews.com logoNivalis Therapeutics Inc (NVLS) Director Acquires $22,600.00 in Stock
www.americanbankingnews.com - May 8 at 4:44 PM
americanbankingnews.com logoNivalis Therapeutics Inc (NVLS) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 6 at 9:26 PM
americanbankingnews.com logoNivalis Therapeutics (NVLS) Earns News Impact Rating of 0.31
www.americanbankingnews.com - May 5 at 10:34 PM
finance.yahoo.com logoNivalis Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 1 at 5:52 PM
marketbeat.com logoNivalis Therapeutics reports 1Q loss
marketbeat.com - May 1 at 5:21 PM
americanbankingnews.com logoNivalis Therapeutics Inc (NVLS) to Release Earnings on Monday
www.americanbankingnews.com - April 29 at 9:38 AM
americanbankingnews.com logoNivalis Therapeutics (NVLS) Receiving Favorable Press Coverage, Study Finds
www.americanbankingnews.com - April 29 at 12:56 AM
americanbankingnews.com logoNivalis Therapeutics Inc (NVLS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 28 at 6:41 PM
zacks.com logoWhat's in Store for Nivalis (NVLS) this Earnings Season?
www.zacks.com - April 26 at 6:19 PM
americanbankingnews.com logoNivalis Therapeutics (NVLS) Getting Somewhat Favorable News Coverage, Study Shows
www.americanbankingnews.com - April 25 at 8:02 PM
americanbankingnews.com logoZacks Investment Research Upgrades Nivalis Therapeutics Inc (NVLS) to Buy
www.americanbankingnews.com - April 23 at 5:38 PM
americanbankingnews.com logoNivalis Therapeutics (NVLS) Earns Daily News Sentiment Score of 0.16
www.americanbankingnews.com - April 22 at 3:52 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Nivalis Therapeutics Inc (NVLS) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - April 21 at 3:41 PM
finance.yahoo.com logo[$$] Alpine Immune Sciences To Go Public Through Reverse Merger With Nivalis
finance.yahoo.com - April 21 at 12:04 AM
americanbankingnews.com logoNivalis Therapeutics Inc (NVLS) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - April 19 at 6:52 PM
americanbankingnews.com logoNivalis Therapeutics (NVLS) Getting Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - April 19 at 12:12 PM
benzinga.com logoWall Street's M&A Chatter From April 18: Akorn, Cardinal Health, Post-Weetabix, Nivalis Therapeutics-Alpine Immune
www.benzinga.com - April 19 at 10:09 AM
streetinsider.com logoNivalis Therapeutics (NVLS) to Merge with Alpine Immune Sciences in All-Stock Deal
www.streetinsider.com - April 19 at 10:09 AM
finance.yahoo.com logoColorado biotech firm is being acquired to create $90M company in Seattle
finance.yahoo.com - April 19 at 10:09 AM
finance.yahoo.com logoFormer Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger
finance.yahoo.com - April 18 at 6:18 PM
americanbankingnews.com logoNivalis Therapeutics (NVLS) Earns Media Impact Rating of 0.47
www.americanbankingnews.com - April 13 at 11:09 AM
americanbankingnews.com logoNivalis Therapeutics Inc (NVLS) Lifted to Buy at Vetr Inc.
www.americanbankingnews.com - April 2 at 10:33 AM
americanbankingnews.com logoNivalis Therapeutics Inc (NVLS) Lifted to "Buy" at Vetr Inc.
www.americanbankingnews.com - April 2 at 12:04 AM
investopedia.com logoVertex Pharma Cystic Fibrosis Combo Succeeds (VRTX)
www.investopedia.com - March 29 at 9:25 AM
americanbankingnews.com logoVetr Inc. Lowers Nivalis Therapeutics Inc (NVLS) to Sell
www.americanbankingnews.com - March 26 at 11:10 AM
finance.yahoo.com logoAntares Pharma Inc. and Nivalis Therapeutics Inc. Show Resiliency as They Snap Back from Late 2016 Uncertainties
finance.yahoo.com - March 15 at 9:46 AM
streetinsider.com logoNivalis Therapeutics (NVLS) Says Cavosonstat Phase 2 Clinical Trial in CF Missed Primary Endpoint
www.streetinsider.com - February 24 at 12:02 AM
us.rd.yahoo.com logoNivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat Added to Ivacaftor for Treatment of Cystic Fibrosis
us.rd.yahoo.com - February 23 at 7:01 PM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 23 at 7:01 PM
finance.yahoo.com logoNIVALIS THERAPEUTICS, INC. Financials
finance.yahoo.com - February 17 at 4:36 PM
us.rd.yahoo.com logo4:14 pm Nivalis Therapeutics beats on Q4 EPS
us.rd.yahoo.com - February 14 at 1:07 AM
rttnews.com logoEARNINGS SUMMARY: Details of Nivalis Therapeutics, Inc. Q4 Earnings Report
www.rttnews.com - February 13 at 8:06 PM
us.rd.yahoo.com logoNivalis Therapeutics Reports Fourth Quarter and Full-Year 2016 Financial Results
us.rd.yahoo.com - February 13 at 8:06 PM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
biz.yahoo.com - February 13 at 8:06 PM
bizjournals.com logoColorado biotech slashes staff, axes CEO
www.bizjournals.com - January 13 at 11:40 PM
nasdaq.com logoNivalis Therapeutics To Eliminate 25 Jobs, Including CEO
www.nasdaq.com - January 13 at 12:34 AM
streetinsider.com logoNivalis Therapeutics (NVLS) Approves Corporate Restructuring; CEO to Step Down
www.streetinsider.com - January 13 at 12:34 AM
finance.yahoo.com logoNivalis Therapeutics Announces Corporate Restructuring
finance.yahoo.com - January 12 at 7:33 PM
finance.yahoo.com logo4:12 pm Nivalis Therapeutics Board of Directors has approved a restructuring plan as part of the initiative to explore strategic alternatives; cutting 25 of 30 employees, including the CEO and CMO
finance.yahoo.com - January 12 at 7:33 PM
biz.yahoo.com logoNIVALIS THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors
biz.yahoo.com - January 12 at 7:33 PM
marketwatch.com logoNivalis to lay off CEO and 80% of staff as part of restructuring
www.marketwatch.com - January 12 at 7:33 PM
bizjournals.com logoTrump triggers Colorado biotech stock sell-off after targeting drug industry (Video)
www.bizjournals.com - January 11 at 7:35 PM

Social

Chart

Nivalis Therapeutics (NVLS) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff